

RESEARCH ARTICLE

Mixed infections by different *Trypanosoma cruzi* discrete typing units among Chagas disease patients in an endemic community in Panama

Alexa Prescilla Ledezma^{1,2}, Roberto Blandon³, Alejandro G. Schijman⁴, Alejandro Benatar⁴, Azael Saldaña^{2,5}, Antonio Osuna^{1*}

1 Institute of Biotechnology, Department of Parasitology, University of Granada, Granada, Spain, **2** Center for Research and Diagnosis of Parasitic Diseases (CIDEP), Faculty of Medicine, University of Panama, Panama, Panama, **3** Cardiology Service, Santo Tomas Hospital, Panama, Panama, **4** Laboratory of Molecular Biology of Chagas Disease, Institute of Research in Genetic Engineering and Molecular Biology "Dr Héctor Torres" (INGEBI-CONICET), Buenos Aires, Argentina, **5** Gorgas Memorial Institute of Health Studies (ICGES), Panama, Panama

* aosuna@ugr.es



OPEN ACCESS

Citation: Ledezma AP, Blandon R, Schijman AG, Benatar A, Saldaña A, Osuna A (2020) Mixed infections by different *Trypanosoma cruzi* discrete typing units among Chagas disease patients in an endemic community in Panama. PLoS ONE 15 (11): e0241921. <https://doi.org/10.1371/journal.pone.0241921>

Editor: Luzia Helena Carvalho, Instituto Rene Rachou, BRAZIL

Received: May 27, 2020

Accepted: October 22, 2020

Published: November 12, 2020

Copyright: © 2020 Ledezma et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the manuscript and its [Supporting Information](#) files.

Funding: Financial Disclosure: Financial support from the Instituto Carlos III, Ministerio de Sanidad, Gobierno de España through the ERANet program and Fundación Ramón Areces. Thanks to the funded projects Research in Prevention of Congenital CHAGAS DISEASE: Parasitological, placental and immunological markers". ELAC2014/

Abstract

Background

Trypanosoma cruzi, the hemoparasite that causes Chagas disease, is divided into six Discrete Typing Units or DTUs: TcI-TcVI plus Tcbat. This genetic diversity is based on ecobiological and clinical characteristics associated with particular populations of the parasite. The main objective of this study was the identification of DTUs in patients with chronic chagasic infections from a mountainous rural community in the eastern region of Panama.

Methods

A total of 106 patients were tested for Chagas disease with three serological tests (ELISA, rapid test, and Western blot). Molecular diagnosis and DTU typing were carried out by conventional PCRs and qPCR targeting different genomic markers, respectively. As a control sample for the typing, 28 patients suspected to be chagasic from the metropolitan area of Panama City were included.

Results

Results showed a positivity in the evaluated patients of 42.3% (33/78); high compared to other endemic regions in the country. In the control group, 20/28 (71.43%) patients presented positive serology. The typing of samples from rural patients showed that 78.78% (26/33) corresponded to TcI, while 9.09% (3/33) were mixed infections (TcI plus TcII/V/VI). Seventy-five percent (15/20) of the patients in the control group presented TcI, and in five samples it was not possible to typify the *T. cruzi* genotype involved.

HID-0328" and "Research in prevention of Congenital Chagas Disease: Parasitological, placental and immunological markers" ERANet17/HLH-0142 (Cochaco), and "Interactoma de las Exovesículas de *T. cruzi* y de los inmunocomplejos que forman con las células del hospedador; Implicaciones en la patología de la Enfermedad de Chagas", Fundación Ramón Areces, 2019 and project PGC2018-099424-B-I00 from Ministerio de Ciencia y Tecnología. Gobierno de España. APL thanks to the Excellence scholarship program of the Secretaría Nacional de Ciencia Tecnología e Innovación (SENACYT) and Instituto para la Formación y Aprovechamiento de Recursos Humanos (IFARHU), Government of Panama. AS thanks To the National Research System (SNI-SENACYT-PANAMA) for the supporting.

Competing interests: The authors have declared that no competing interests exist

Conclusions

These results confirm that TcI is the main DTU of *T. cruzi* present in chronic chagasic patients from Panama. However, the circulation of other genotypes (TcII/V/VI) in this country is described for the first time. The eco-epidemiological characteristics that condition the circulation of TcII/V/VI, as well as the immune and clinical impact of mixed infections in this remote mountainous region should be investigated, which will help local action programs in the surveillance, prevention, and management of Chagas disease.

Introduction

Chagas disease or American trypanosomiasis is a zoonosis spread from the southern USA to approximately the Río Negro in Argentina, whose causative agent is the hemoparasite *Trypanosoma cruzi* [1]. This infection is transmitted to humans through different routes: i) by direct contamination of the mucosa with the feces of the vector triatomine insects; ii) by ingesting food contaminated with the feces of the vectors; iii) by congenital vertical transmission, and iv) by blood transfusions or transplants of infected organs [1–4]. Currently, the estimated number of patients infected with *T. cruzi* is 6–8 million and 120 million people are at risk of infection. Chagas disease is the most important parasitic disease in Latin America and one of the most common neglected diseases worldwide [5, 6]. The disease is characterized by an acute phase that occurs in most cases asymptotically or with nonspecific symptoms such as fever, malaise and hepatomegaly [7, 8]. Mortality during this acute phase is low (<5%) and mostly linked to myocarditis or meningoencephalitis [9, 10]. Approximately two months after the onset of infection, the chronic phase starts in 70% of the patients and there may be no symptoms even after many years of evolution [11, 12]. The remaining 30% of chronic patients develop heart disease of different degrees, representing the majority of deaths due to Chagas disease [4, 13]. In addition, 10% of these patients may also develop digestive alterations such as megacolon and megasophagus as well as neurological alterations or a combination of both [4, 14, 15].

One of the possible causes of the diversity of the clinical manifestations of Chagas disease has been attributed to the high genetic variability and the multiclonal character of the natural populations of *T. cruzi*. [16]. This diversity has been demonstrated by different research groups based on the marked variety among the different clones of the parasite [17]. Among the differences studied, histotropism, intracellular invasion and multiplication capacity, vector infectivity, drug sensitivity, morphology of trypomastigote forms, antigenic profile and potential association to pathologies are mentioned. Different genotypic markers have allowed the current identification of six discrete typing units, or DTUs, among the different *T. cruzi* isolates plus a different variant identified as TcBat [18]. The enormous genetic variability found in this species favors the appearance of these "strains", which complicates the classification according to their pathology or other phenotypic peculiarities [19].

The geographical distribution of DTUs is particular, as well as their link with reservoirs, transmission cycles, and diagnostic methods [16, 20, 21].

TcI is currently considered one of the parasite's parental lineages [22]. Geographically, TcI predominates in the Andes region, in Central and North America, Mexico [23–25], presenting a sylvatic transmission cycle, mainly between marsupials and sylvatic triatomines [26–28]. This DTU is also associated with human infections reported from the United States [29], Mexico, Central America [30, 31], and northern South America, having been detected in patients with cardiomyopathies from Venezuela [32] and Colombia [33–37].

DTUs (II, III, IV and V) have been found in vector insects, both in Colombia and Venezuela as well as in the rest of South America [38, 39]. DTU II has been described as the cause of parasitism in humans in both acute and chronic cases, as well as in vectors from Colombia, and this DTU is considered to correspond to a primarily domiciliary cycle [40, 41].

Chagasic infection has been known in Panama since 1930 [42, 43]. In 2005, the Pan-American Health Organization (PAHO) estimated, based on official data, that the seroprevalence in this country was 0.01% [44]. Subsequent studies located the rural regions near the Panama Canal as the areas with the highest number of cases [43, 45, 46]. Recent research confirmed that the infection is also common in other areas located west and east of the capital city [47–49]. In contrast, there are still remote rural communities with the appropriate eco-epidemiological conditions for the transmission of Chagas disease where correct epidemiological surveillance has not been implemented [49–51]. From 2007 to 2017, an average of 56 annual cases of Chagas disease were reported in Panama, for a total population of about 4,159,000 inhabitants [52]. Although these figures are below those reported in other countries of Central and South America [49], chagasic infection in Panama is still an important public health concern [53]. In Panama, the main Chagas disease vector is *Rhodnius pallescens*, a triatomine present in the *Attalea butyracea* palm, which is often found in peridomestic areas of endemic communities and that invades nearby dwellings, but does not settle inside them [37, 54–56]. On the other hand, the clinical characteristics related to Chagas disease in Panama involve heart diseases similar to those described in other regions of the continent [25, 57, 58]. However, until now no clinical cases of Chagas disease with digestive pathologies have been described in Panama [42, 59].

The genetic variants of circulating *T. cruzi* in vectors and acute patients have been partially investigated in Panama [25, 49]. Yet, in these preliminary studies, only *T. cruzi* TcI was detected [57, 60] as well as the typification of a *T. cruzi* isolate from a rural area of the Arraiján district [17].

Currently, there are no investigations being carried out aimed at the identification of *T. cruzi* DTUs from blood samples from Panamanian patients. This type of study reflects the genetic diversity of parasites in natural infections without the need for their isolation or expansion, a particularly difficult situation in chronic patients with very low parasitemias [57, 61].

Moreover, genotyping of cultured parasite isolates may lead to misidentification of minor genotypes in mixed infections, since populations that grow at a higher rate are more likely to be detectable by the available typing approaches.

Although information on the distribution of DTUs in different geographical areas is increasing, confirmed association with the clinical manifestations and epidemiology of Chagas disease is limited. As there is a new focus of Chagas disease in Panama, it is relevant to propose ecobiological studies of *T. cruzi* infection in this region of the country aiming to improve surveillance and control measures.

The main objective of the study was the direct identification of *T. cruzi* DTUs in blood samples from chronic chagasic patients resident in this new highly endemic rural community, “Las Margaritas”, Chepo district, Panama province, in comparison to the DTUs detected in Chagas disease patients in the metropolitan area of Panama City, representative of *T. cruzi* infected people in the main endemic regions of the country.

Materials and methods

Ethical statement

All protocols involving human subjects were approved by the Bioethics Committee of Santo Tomás Hospital in Panama City and were assigned the identification code No. 2015–310 V1. A

total of 106 enrolled patients signed written or oral informed consent forms. Individuals who could not read, stamped their fingerprint on the document, in the presence of two witnesses. Acceptance of informed consent was carried out before the study activities were initiated and the analysis was performed according to the approved guidelines. Individuals over 18 years of age signed the consent form and responded to the social and epidemiological questionnaire. Parents and/or guardians of children and youth under 18 years of age provided their written consent for the collection of blood and responded to the social and epidemiological questionnaire.

Patients and sampling

The study was carried out between April 2016 and January 2017 in two different epidemiological settings: 1) a small rural community (Charare), located in a mountainous area, in the township of Las Margaritas, Chepo district, Panama province (coordinates 9.243640, -79.059162) (Fig 1).

The total population of Charare is approximately 250 inhabitants. Sampling was done for convenience; all inhabitants were invited to participate through messages on a local radio station. The total number of samples studied was 106; 73.58% (78/106) corresponding to residents of Charare and 2) a total of 28 suspected chagasic patients diagnosed in the metropolitan area of Panama City, of whom 20/28 (71.42%) presented positive serology. All these patients also signed the informed consent form. This group of patients represents the *T. cruzi* infected population from the main endemic regions of the country, as many of whom travelled to Panama City to be admitted to hospitals. Therefore, their parasitic populations are representative of the main circulating genetic variants of the parasite in the country. All hospitalized cases




Fig 1. The locations of seropositive patients: Chararé community, Las Margaritas district, Chepo district, Panama province. The Map has been drawn by the authors, as well as the photos that are original.

<https://doi.org/10.1371/journal.pone.0241921.g001>

with positive serology had been diagnosed due to their clinical manifestations: repolarization disorders, atrioventricular block, bradycardia, and conduction disorder. The diagnoses were made in the tertiary care hospitals included in the study (Santo Tomás Hospital, Dr. Arnulfo Arias Madrid Hospital Complex, and Omar Torrijos Herrera Hospital for Pediatric Specialties), using ARCHITECT System® Chagas assay (Abbott, Germany). Reconfirmation of *T. cruzi* infection was carried out in all rural and urban cases, using at least two immunological tests as described below. All urban patients had undergone specialized medical evaluation in the respective hospitals. In the case of patients from the rural community, once the serological diagnosis was made, they were clinically evaluated at the Regional Hospital of Chepo district, where they were evaluated and treated according to the clinical characteristics found.

The total number of patients with positive serology evaluated in the study was 53, and 20 of whom were treated at third-level hospitals in Panama City distributed as follows: 13 at the Cardiology service of Santo Tomás Hospital, four diagnosed at the Blood Bank of the Social Security Fund and two at the Infectology Outpatient Clinic of the Dr. Arnulfo Arias Madrid Hospital Complex of the Social Security Fund.

Thirty-three of the seropositive patients corresponded to the rural areas, all of whom permanent residents in the community of Chararé.

All individuals who agreed to participate in the study had two venous blood samples taken. The first sample of approximately 5 ml was collected in a Vacutainer™ EDTA vacuum blood collection tube for molecular assays. The blood sample was mixed 1:1 with a 6M guanidine hydrochloride solution (Sigma, St. Louis, USA.) and 200 mM EDTA, pH 8.0 (GEB) [62]. These samples were kept at laboratory temperature (22° C) for at least 4 days. For the second sample, BD Vacutainer™ Venous Blood Collection Tubes were used (Vacutainer Plus™ Glass Serum Tube), and 5 ml of blood were taken. After the clot formed, each tube was centrifuged at 1,500 x g for 10 min and approximately 2.0 ml of serum were collected to carry out the different serological tests.

Serological tests

The presence of anti-*T. cruzi* antibodies in the different samples was confirmed by commercial tests of recombinant ELISA Chagatest, Wiener Lab, Argentina. Briefly, 10 µL of each serum sample were used and diluted with 200 µL of the sample diluent, then incubated for 30 min at 37°C, and washed 5 times with diluted 1:5 washing buffer. Next, 50 µL of the conjugate (peroxidase-conjugated anti-human (goat) immunoglobulins) were added and incubated for 30 minutes at 37°C. Subsequently, 5 washes were carried out with 300 µL thereof and the residue was completely aspirated. After the washings were completed, 50 µL of each of the developers were added: A (hydrogen peroxide 60 mmol / l in citrate buffer 50 mmol / L pH 3.2) and B (tetramethylbenzidine (TMB) 0.01 mol / l in 0.1 N hydrochloric acid) by incubating the wells for 30 minutes at room temperature. Finally, 50 µL of stop solution (2N sulfuric acid) were added and the reading was carried out at 490 nm in a Multiskan® Spectrum reader (Thermo Fisher Scientific, Finlandia). Both negative (non-reactive, inactivated serum dilution) and positive (inactivated serum dilution containing antibodies against *T. cruzi*) samples were performed in triplicate.

The SD Bioline Chagas AB Rapid test (Abbott, Germany) was used, following the manufacturer's instructions. Briefly, 100 µL of the study serum were added to the sample well and 50 µL of the assay buffer (100 mM Tris-CI (5 ml) were added. It was then incubated at room temperature for 15 minutes. The test was read visually after 15 minutes. Any positive sample with the Chagas Ab SD Bioline Rapid Test was confirmed with alternate test methods. As a complementary assay, an immunoblot test of a Panamanian isolate of *T. cruzi* was used

following the methodology described [63]. Briefly, each membrane was incubated with a 1:100 dilution (in milk solution) of the sera of the evaluated patients. Incubation was carried out under shaking, at room temperature, overnight, in 2.5ml tubes containing the nitrocellulose strip and 700µl of the respective serum dilution. The strip was then washed 3 times with PBS and incubated with human anti-immunoglobulin conjugate (DAKO IgG, IgM and IgA) diluted at 1:700 in PBS for one hour. Then, each strip was washed 3 times with PBS, before adding the substrate-chromogen (H₂O₂, PBS, NiCl, diaminobenzidine); the reaction was stopped with tap water, after approximately 10 minutes. The strips were photographed for the interpretation of the generated profiles.

The patients were considered positive when they showed positivity in at least two of the three immunological tests.

A questionnaire containing demographic information and indicators of knowledge, attitudes and risk factors for the transmission of Chagas disease as well as the mode of transmission, main clinical characteristics and biology of the vector (habits and ecotope, among others) was given to each patient with positive serology for chagasic infection ([S1 Questionnaire](#)). An anonymous identification number was used to identify information in the questionnaires.

DNA extraction

DNA extraction from blood samples was carried out using a commercially available kit (High Pure PCR Template preparation kit, Roche Applied Science), following the manufacturer's instructions. For the extraction of DNA, 500 µl of GEB were used and finally eluted in 100 µl ultrapure water. The extracted DNA was stored at -20°C until further analysis [64, 65].

Polymerase chain reaction for the detection of *Trypanosoma cruzi*

Trypanosoma cruzi DNA detection was performed by PCR analysis in a CFX96™ Real-Time System thermal cycler CFX-96 Real Time System (Bio-Rad Laboratories). The reaction mixture was made with a 1X Go Taq® flexi buffer amplification buffer, 25 mM dNTPs, 2.5 mM MgCl₂, 1.0 U of Go Taq® (Promega, USA), 10 pmol of specific primers 121 (AAATAATGTACGGGKGAGATGCATGA) and 122 (GGTTCGATTGGGGTTGGTGTAATATA) according to the methodology described [66]. The amplification conditions consisted of two cycles, each of 1 min at 98°C and 2 min at 64°C, followed by 33 cycles of 1 min at 94°C, and 1 min at 64°C, before a final extension at 72°C for 10 min. A DNA sample from *T. cruzi* tripomastigote forms in culture was used as a positive control, and a negative control was run without a DNA sample. PCR products were analyzed by agarose gel electrophoresis with SYBR Green and UV visualization in ChemiDoc MP Imaging System Bio Rad. A 330-bp product was considered indicative of the presence of the kinetoplastid DNA (kDNA) of *T. cruzi*.

Genotyping assays of *T. cruzi* by PCR assays

For the identification of the *T. cruzi* DTUs detectable in the blood samples, a series of PCRs targeting different genomic markers was carried out, following the PCR-based algorithm reported by Burgos and co-authors [65], as described in [S1 Table](#) and [S1 Fig](#). The DTU typing algorithm included the following *T. cruzi* genomic targets:

- (1) the Spliced Leader intergenic region (SL-IR PCR) was used to distinguish *T. cruzi* I (150 bp), II, V, and VI (157 bp) from *T. cruzi* III and IV (200 bp);
- (2) first round and hemi-nested SL-IR-I was used to identify *T. cruzi* I DTUs (475 bp and 350 bp, respectively), and first round and hemi-nested SL-IR-II was used to identify *T. cruzi* II, V, and VI DTUs (425 bp and 300 bp, respectively);
- (3) hemi-nested PCR of 24S α- ribosomal DNA was used to distinguish *T. cruzi* V (125 or 125 + 140 bp) from *T. cruzi* II and VI (140 bp); and
- (4) hemi-nested real-time PCR

targeting the A10 fragment was used to discriminate *T. cruzi* II (580 bp) from *T. cruzi* VI (525 bp). Samples that yielded positive SL-IR-II PCR results but negative 24S α -ribosomal DNA PCR results were reported as *T. cruzi* II, V, or VI (II/V/VI). Samples that amplified the 140-bp 24S α -rDNA fragment but negative results of real-time PCR targeting A10 were reported as *T. cruzi* II or VI, as described [65].

Results and discussion

Of the 78 rural patients evaluated, 42.3% (33/78) were seropositive for *T. cruzi* infection. This percentage suggests the existence of a high prevalence of chagasic infection in this rural area of Panama, when compared to the percentages found in recent studies in other endemic areas, where lower seroprevalences were demonstrated [48]. However, this high frequency of chagasic infection is consistent with sero-epidemiological studies carried out in other near endemic regions. As described by Anez et al. (2004), rural regions of Venezuela have a seropositivity of 56.8%, and in the Arauca region in Colombia, 21.6% of 0 to 14 year-old children tested positive for chagasic infection [32, 67, 68].

In 2010, the Department of Vector Control of the Ministry of Health of Panama reported the presence of the two main vectors of Chagas disease (*R. pallescens* and *Triatoma dimidiata*) in the community of Chararé. Around that time, the first cases of Chagas disease were diagnosed in the community. However, the genetic characteristics of circulating *T. cruzi* populations in the area have hitherto not been studied. This mountainous area is located in a remote region of difficult access, its inhabitants share low eco-epidemiological and socioeconomic characteristics that predispose the transmission of multiple pathogens, including *T. cruzi* (Table 1) [48].

All seropositive cases detected in the Chararé region can be considered chronic Chagas disease patients. Prior to sample collection, none of the patients reported fever or clinical signs that could suggest the acute phase of the disease. *T. cruzi* infection was characterized in these patients by means of a kDNA-based PCR test; 90% out of 20 urban patients were kDNA-PCR positive and 100% of patients from Chararé were kDNA-PCR positive. Genotyping of DTUs of these patients' blood samples was carried out from the same DNA extracts without previous knowledge of the kDNA-PCR result. In fact, kDNA-PCR negative samples did not amplify genes used for DTU typing. Among kDNA-PCR positive samples, it was possible to identify DTUs in 15/18 and 29/33 samples from rural and urban localities (Table 2) and only after amplification of the *T. cruzi* SL-IR I and SL-IR II genes as molecular targets, whereas the other genotyping markers gave non-detectable results. Thus, distinction could only be made between TcI, and Tc II/V/VI DTU groups. These SL-IR I and II based PCR procedures showed that in Chararé, 78.78% of patients were infected with DTU I strains, while 9.09% corresponded to mixed DTU I plus DTU II/V/VI infections. In four of these samples (12.12%), the corresponding DTU group could not be determined (Table 2). The failure to genotype some of the tested samples was probably due to low parasitic loads, below the detection limits of the SL-IR I and II PCR methods (S1 Table) [65, 69]. The same limitation can be suspected for the other genotyping markers that gave undetectable findings.

The kDNA-PCR analysis of seropositive samples from urban chagasic patients, was positive in 18/20 (90%) of the samples. Fifteen of the samples, equivalent to 75%, were infected with Tc I populations and in five samples, it was not possible to typify the *T. cruzi* DTU involved. DTUs III/IV were not detectable in these populations. From the PCR positive data, it can be deduced that the analyzed blood samples from the chronic patients present circulating trypomastigote forms of the parasite as well as amastigote forms resulting from the death and rupture of infected cells, or there is DNA contamination from the kinetoplast of the parasite due to the destruction of the parasite forms and the consequent release of the kDNA. Among

Table 1. Sociodemographic characteristics of the interviewees by area of residence.

Variable	Total n = 53		Urban Patients n = 20		Rural Patients n = 33	
	n	%	n	%	n	%
Sex						
Female	25	47.2	7	40.0	18	54.5
Male	28	52.8	13	60.0	15	45.5
Age						
Less than 25 years	10	18.9	0	0.0	10	30.3
From 25 to 39 years	18	34.0	9	45.0	9	27.3
From 40 to 59 years	17	32.1	9	45.0	8	24.2
Over 60 years	8	15.0	2	10.0	6	18.2
Total	53	100.0	20	100.0	33	100.0
Time of Residence						
	Total n = 43		Urban Patients n = 20		Rural Patients n = 23	
Less Than 1 year	3	7.0	2	10.0	1	4.3
From 2 to 5 years	5	11.6	5	25.0	0	0.0
More than 5 years	35	81.4	13	65.0	22	95.7
Education						
No degree	5	11.6	0	0.0	5	21.7
Primary	21	48.8	7	35.0	14	60.9
High School	10	23.3	6	30.0	4	17.4
Tertiary	3	7.0	3	15.0	0	0.0
University superior	4	9.3	4	20.0	0	0.0
Occupation						
Employee	13	30.2	6	30.0	7	30.4
Self-employed	12	27.9	6	30.0	6	26.1
Domestic work	11	25.6	0	0.0	7	30.4
Unemployed	4	9.3	5	25.0	3	13.1
No answer	3	7.0	3	15.0	0	0.0
Household residents						
1	4	9.3	2	10.0	2	8.7
From 2 to 5	15	34.9	8	40.0	7	30.4
More than 5 people	24	55.8	10	50.0	14	60.9
Patients in the home						
1	38	88.4	20	100.0	18	78.3
2	3	7.0	0	0.0	3	13.1
3	1	2.3	0	0.0	1	4.3
4	1	2.3	0	0.0	1	4.3

<https://doi.org/10.1371/journal.pone.0241921.t001>

seropositive patients diagnosed in urban hospitals (ARCHITECT System Chagas assay), 71.42% (20/28) presented a clinical profile with heart disease evidenced by echocardiogram and chest radiography, and the data of rural endemic community patients were sent to the health services for their clinical evaluation after serological diagnosis. Asymptomatic patients were found in 30.30% (10/33), with some degree of heart disease 18.18% (6/33), in 51.51% (17/33) the clinical evaluation was not performed (S2 Table).

In some samples in which the serological tests showed discrepancies in the positivity results, the PCR verification of the presence of kDNA confirmed infection. Thus, this technique should be incorporated in the diagnostic confirmation of *T. cruzi* infection.

Surveys carried out, both in urban and rural areas showed that among the evaluated patients 53% were male, including 6 children below 15 years of age. With reference to

Table 2. Serological and PCR-based findings in the two patient groups studied. Patients screened with the different methodologies in the two study groups. The presence of 5.6% (3/53) of patients with mixed DTU (DTU I and II/V/VI) is clearly presented.

Samples	Urban Patients	Rural Patients	Total
Total tested samples	28 (26.42%)	78 (73.58%)	106 (100%)
Anti- <i>T. cruzi</i> seroreactivity	20 (71.43%)	33 (42.30%)	53 (50%)
kDNA-PCR positivity	18/20 (90%)	33/33 (100%)	51/53 (96.22%)
DTU PCR positivity	15/20 (75%)	29/33 (87.88%)	44/53 (83.01%)
Tc I	15/20 (75%)	26/33 (78.78%)	41/53 (77.35%)
Mixed	--	3/33 (9.09%)	3/53 (5.66%)*
Tc I + Tc II/V/VI			
Untyped DTUs#	5/20 (25%)	4/33 (12.12%)	9/51 (17.64%)

* The presence of 5.6% (3/53) of patients with mixed DTU (DTU I and II/V/VI) is clearly presented.

The numbers include those cases with nondetectable kDNA-PCR findings plus those kDNA-PCR positive samples that gave nondetectable results in the PCRs performed for DTU genotyping.

<https://doi.org/10.1371/journal.pone.0241921.t002>

socioeconomic data, it was evident that 100% of the rural patients knew about the transmitting insects of Chagas disease and, based on the level and quality of the dwelling, had had repeated contact with these insects. An outstanding finding was the fact that up to four seropositive patients living in the same family unit were reported in the Chararé community (Table 1). This contrasts with the urban patients, of whom everyone knew both, the disease and the insect vector, but most of whom did not remember direct contact with the insect. The diagnosed urban patients reported being the only infected individuals in their family units after all their family members had been assessed. In all cases, regular periodic stays and overnight stays had been reported in rural areas, respectively, areas with high *Ataltea* palm density.

The rural community of Chararé is a community with marked poverty and without easy land access, having scarce health resources, and living on subsistence economy based on agriculture, with 56.52% working on their own or in domestic work, and only 30% are salaried. A high percentage, 95.65% of those surveyed had been living in the community for more than 5 years, living with a large variety of domestic/wild animals and frequently exposed to the presence of triatomine vectors. Most of its inhabitants (82.60%) had received basic education (primary and secondary), while 21.73% had no education, being unaware of many aspects of the symptomatology, pathology, treatment or control of the disease (Table 1).

The significant levels of seropositivity found in this study should be considered by the country's health authorities in order to implement better surveillance, prevention, and control programs for this parasitosis.

As for the urban population, 65% had received basic education, and 35% had attended higher education or university, thus having a better understanding of the relevant aspects of Chagas disease. The salaried population is 30%, evidencing in both groups and with high percentage of large families (Table 1).

The clinical manifestations of chagasic infection in Panama are primarily cardiac during both the acute and chronic phases of the disease, with no evidence that the digestive form develops during the later stages of infection [43].

The pattern of Chagas disease in Panama seems to be similar to that of other regions such as Venezuela, Colombia and Central America, where cardiac manifestations prevail [17, 70, 71]. In this sense, and based on the diverse ecobiological conditions existent in Panama, it is likely that, as in other regions of northern South America, DTUs other than TcI are in circulation, both in vectors and in reservoirs. The ecoepidemiological conditions, not fully known in this region, could explain the existence of different DTUs. The import of

infected animals or the arrival of foreign vectors is much more complex since the area is remote and difficult to access. A study in Colombia [72] detected the presence of esophageal achalasia associated with Chagas disease, induced by TcI, present in patients diagnosed with this pathology. On the other hand, in Colombia, chagasic patients with mixed cardiac and gastrointestinal involvement were reported, and the genotyping of the tissue samples showed both, TcI in the affected esophagus and TcII in the heart samples [73]. Similarly, mixed infections in insects involving different DTUs (DTU II, III and IV) have been reported [38]. Although in Colombia, DTU I has been reported in most patients, insect vectors and reservoirs, the existence of TcII strains has also been reported in chronic chagasic patients [73]. Likewise, in Venezuela, in ecotopes similar to those evaluated in Panama, human infections caused by TcI and TcII strains and mixed infections in cardiac tissue have been detected with DTUs I, II, III and IV strains [38, 74].

Similar studies suggest that genetically related populations of *T. cruzi* possibly exist in the same or adjacent geographic areas and could be involved in determining the development of the same clinical form of the disease. In a study carried out by Vago et al. (2000), multiclonal strains in the heart and esophagus were found, evidencing the first data of possible human differential tissue tropism [75]. Among the three patients with mixed infections (cases 31, 33 and 36) S2 Table, all were residents of Chepo, Las Margaritas and two of them (cases 31 and 36) had cardiac manifestations, while the remainder (case 33) was asymptomatic. As the latter patient was only 14 years old when tested, it cannot be ruled out that, if not treated, she would have developed cardiac disease. On the other hand, taking into consideration the histotropism hypothesis (48), we cannot discard that the other patients studied harbor non-Tc I genotypes that could not be detected in peripheral blood in the samples taken. Follow-up of patients residing in this locality, and especially patients belonging to the families exhibiting mixed infections, would be of much interest in order to find out if genotypes other than TcI may emerge at different lifetime periods along the natural history of their chronic infection.

Research carried out in the Gran Chaco, Argentina, revealed mixed infections of human TcV / TcVI and canine TcI / TcVI in rural areas, demonstrating significant associations between TcV with humans and TcVI with dogs. They also found TcIII, TcI and TcV in dogs and for the first time described TcIII in humans in this area, suggesting that there is contact with wild mammals during hunting or that Tc III may be involved in the domestic cycle [76].

On the other hand, experimental studies carried out in dogs with *T. cruzi* Y (TcII) or Col (TcI) have shown that infection by *T. cruzi* can be caused by different strains of different DTUs that favor variable clinical forms of chronic Chagas disease, so that the immune response and cardiac lesions can be evaluated. The Col (TcI) strain escapes the host's acute immune response, goes unnoticed by peripheral blood mononuclear cells, and therefore parasitizes organs more rapidly. In contrast, strain Y (TcII), the specific immune response begins in the acute phase, which helps control myocardial injury in the early chronic phase [77]. Similarly, experimental studies in mice refer to Chagas disease heterogeneity from diverse aspects such as organ damage, parasite tropism, immune response, infection phase and strain [78–80].

Studies performed by Mining and coworkers [19], using whole genome tiling arrays for comparative genome analysis of cultured parasite stocks, have revealed that there is much more genotypic diversity among *T. cruzi* strains than can be understood using traditional typing methods. In particular, within Tc I, their typing results, together with studies based on microsatellite analyses of Tc I strains [81], indicate that there is substantially more genetic diversity among Tc I strains than there is among other DTUs. Accordingly, further investigation in isolates from Panama would be needed to assert the intra-DTU variability of circulating Tc I genotypes and their possible transmission cycles.

Conclusions

Our findings in Chararé confirm TcI as the main circulating DTU in chronic Chagas disease patients from Panama and describe, for the first time, minority cases of coinfections with parasite populations belonging to non-Tc I genotypes, such as Tc II, Tc V or Tc VI. The presence of chagasic infections with mixed genetic variants of the parasite in rural areas justifies eco-epidemiological and clinical studies in this new endemic area for Chagas disease in Panama. These investigations should aim to describe the eco-epidemiological implications of the circulation of these DTUs that coinfect together with TcI this region of the country, either as a result of the entry of vectors, wild or domestic mammalian reservoirs, or through human migration in this region framed in the natural passage between South America and Central America. It is also a pending task to determine if these new genetic variants of *T. cruzi* detected are native.

Supporting information

S1 Fig. Flow-chart of PCR procedures for DTU genotyping in blood samples from chronic Chagas disease patients. Agarose Gels showing amplicons obtained by SL-IR (a), SL-IR I and SL-IR II (b), 24S α rDNA Heminested (c) and A10 fragment Heminested (d) based PCR assays. (TIF)

S1 Table. PCR-based algorithm for Typing DTUs in clinical samples. Primer sequences and amplification conditions. (DOC)

S2 Table. Characterization of *T. cruzi* in blood samples from chronic patients with Chagas disease from Panama. HN +: DTU detection by hemi-nested PCR. * HN +: DTU detection by hemi-nested PCR. Untyped: samples that gave nondetectable findings using the DTU typing algorithm. (DOCX)

S1 Questionnaire. (DOCX)

S1 File. (DOCX)

S2 File. (DOCX)

S3 File. (DOCX)

S4 File. (DOC)

S5 File. (DOCX)

Acknowledgments

The authors thank the students of the School of Medical Technology, Faculty of Medicine, University of Panama for the application of the surveys, the Department of Human

Microbiology of the Faculty of Medicine, University of Panama, the medical and laboratory personnel of the different hospitals that participated in the study for their voluntary collaboration.

Author Contributions

Conceptualization: Roberto Blandon, Alejandro G. Schijman, Azael Saldaña, Antonio Osuna.

Data curation: Roberto Blandon.

Formal analysis: Antonio Osuna.

Funding acquisition: Antonio Osuna.

Investigation: Alexa Prescilla Ledezma, Alejandro G. Schijman, Alejandro Benatar, Azael Saldaña, Antonio Osuna.

Methodology: Alexa Prescilla Ledezma, Alejandro G. Schijman, Alejandro Benatar, Azael Saldaña, Antonio Osuna.

Supervision: Alejandro G. Schijman, Azael Saldaña.

Validation: Azael Saldaña.

Visualization: Alexa Prescilla Ledezma, Azael Saldaña.

Writing – original draft: Alexa Prescilla Ledezma, Alejandro G. Schijman, Azael Saldaña, Antonio Osuna.

Writing – review & editing: Alexa Prescilla Ledezma, Alejandro G. Schijman, Azael Saldaña, Antonio Osuna.

References

1. World Health Organization. Chagas disease in Latin America: an epidemiological update based on 2010 estimates. *Relev Epidemiol Hebd.* 2015 Feb 6; 90(6):33–43. PMID: [25671846](https://pubmed.ncbi.nlm.nih.gov/25671846/)
2. Santos FLN, de Souza WV, Barros M da S, Nakazawa M, Krieger MA, Gomes Y de M. Chronic Chagas Disease Diagnosis: A Comparative Performance of Commercial Enzyme Immunoassay Tests. *Am J Trop Med Hyg.* 2016 May 4; 94(5):1034–9. <https://doi.org/10.4269/ajtmh.15-0820> PMID: [26976886](https://pubmed.ncbi.nlm.nih.gov/26976886/)
3. Galán-Puchades MT, Osuna A. Medical Considerations before International Travel. *N Engl J Med.* 2016 Oct 13; 375(15):e32.
4. Flores-Chavez MD, Sambri V, Schottstedt V, Higuera-Escalante FA, Roessler D, Chaves M, et al. Evaluation of the Elecsys Chagas Assay for Detection of *Trypanosoma cruzi*-Specific Antibodies in a Multi-center Study in Europe and Latin America. Fenwick B, editor. *J Clin Microbiol.* 2018 Feb 14; 56(5).
5. Andrade D V, Gollob KJ, Dutra WO. Acute chagas disease: new global challenges for an old neglected disease. *PLoS Negl Trop Dis.* 2014; 8(7):e3010. <https://doi.org/10.1371/journal.pntd.0003010> PMID: [25077613](https://pubmed.ncbi.nlm.nih.gov/25077613/)
6. Balouz V, Agüero F, Buscaglia CA. Chagas Disease Diagnostic Applications: Present Knowledge and Future Steps. *Adv Parasitol.* 2017; 97:1–45. <https://doi.org/10.1016/bs.apar.2016.10.001> PMID: [28325368](https://pubmed.ncbi.nlm.nih.gov/28325368/)
7. Nunes MCP, Dones W, Morillo C a., Encina JJ, Ribeiro AL. Chagas disease: An overview of clinical and epidemiological aspects. *J Am Coll Cardiol.* 2013; 62(9):767–76. <https://doi.org/10.1016/j.jacc.2013.05.046> PMID: [23770163](https://pubmed.ncbi.nlm.nih.gov/23770163/)
8. Tanowitz HB, Machado FS, Spray DC, Friedman JM, Weiss OS, Lora JN, et al. Developments in the management of Chagas cardiomyopathy. *Expert Rev Cardiovasc Ther.* 2015 Dec; 13(12):1393–409. <https://doi.org/10.1586/14779072.2015.1103648> PMID: [26496376](https://pubmed.ncbi.nlm.nih.gov/26496376/)
9. Rassi A, Rassi A, Marin-Neto JA. Chagas disease. *Lancet.* 2010 Apr 17; 375(9723):1388–402. [https://doi.org/10.1016/S0140-6736\(10\)60061-X](https://doi.org/10.1016/S0140-6736(10)60061-X) PMID: [20399979](https://pubmed.ncbi.nlm.nih.gov/20399979/)
10. Bonney KM. Chagas disease in the 21st century: a public health success or an emerging threat? *Parasite.* 2014; 21:11. <https://doi.org/10.1051/parasite/2014012> PMID: [24626257](https://pubmed.ncbi.nlm.nih.gov/24626257/)

11. Abel LC., Rizzo L V, Ianni B, Albuquerque F, Bacal F, Carrara D, et al. Chronic Chagas' Disease Cardiomyopathy Patients Display an Increased IFN- γ Response to *Trypanosoma cruzi* Infection. *J Autoimmun.* 2001 Aug; 17(1):99–107. <https://doi.org/10.1006/jaut.2001.0523> PMID: 11488642
12. Teixeira ARL, Hecht MM, Guimaro MC, Sousa AO, Nitz N. Pathogenesis of chagas' disease: parasite persistence and autoimmunity. *Clin Microbiol Rev.* 2011 Jul; 24(3):592–630. <https://doi.org/10.1128/CMR.00063-10> PMID: 21734249
13. Sousa GR, Gomes JAS, Fares RCG, Damásio MPDS, Chaves AT, Ferreira KS, et al. Plasma cytokine expression is associated with cardiac morbidity in chagas disease. Goldberg AC, editor. *PLoS One.* 2014 Jan 6; 9(3):e87082. <https://doi.org/10.1371/journal.pone.0087082> PMID: 24603474
14. Gascón J, Albajar P, Cañas E, Flores M, Gómez i Prat J, Herrera RN, et al. Diagnóstico, manejo y tratamiento de la cardiopatía chagásica crónica en áreas donde la infección por *Trypanosoma cruzi* no es endémica. *Rev Española Cardiol.* 2007 Mar; 60(3):285–93.
15. Sánchez-Montalvá A, Moris M, Mego M, Salvador F, Accarino A, Ramírez K, et al. High Resolution Esophageal Manometry in Patients with Chagas Disease: A Cross-Sectional Evaluation. *PLoS Negl Trop Dis.* 2016 Feb; 10(2):e0004416. <https://doi.org/10.1371/journal.pntd.0004416> PMID: 26848957
16. Macedo AM, Pena SDJ. Genetic Variability of *Trypanosoma cruzi*: Implications for the Pathogenesis of Chagas Disease. *Parasitol Today.* 1998 Mar 3; 14(3):119–24. [https://doi.org/10.1016/s0169-4758\(97\)01179-4](https://doi.org/10.1016/s0169-4758(97)01179-4) PMID: 17040719
17. Cura CI, Mejía-Jaramillo AM, Duffy T, Burgos JM, Rodríguez M, Cardinal M V., et al. *Trypanosoma cruzi* I genotypes in different geographical regions and transmission cycles based on a microsatellite motif of the intergenic spacer of spliced-leader genes. *Int J Parasitol.* 2010 Dec 1; 40(14):1599–607. <https://doi.org/10.1016/j.ijpara.2010.06.006> PMID: 20670628
18. Zingales B, Andrade S, Briones M, Campbell D, Chiari E, Fernandes O, et al. A new consensus for *Trypanosoma cruzi* intraspecific nomenclature: second revision meeting recommends TcI to TcVI. *Mem Inst Oswaldo Cruz.* 2009 Nov; 104(7):1051–4. <https://doi.org/10.1590/s0074-02762009000700021> PMID: 20027478
19. Minning TA, Weatherly DB, Flibotte S, Tarleton RL. Widespread, focal copy number variations (CNV) and whole chromosome aneuploidies in *Trypanosoma cruzi* strains revealed by array comparative genomic hybridization. *BMC Genomics.* 2011 Dec 7; 12(1):139.
20. Llewellyn MS, Lewis MD, Acosta N, Yeo M, Carrasco HJ, Segovia M, et al. *Trypanosoma cruzi* IIc: Phylogenetic and phylogeographic insights from sequence and microsatellite analysis and potential impact on emergent Chagas disease. Huete-Pérez JA, editor. *PLoS Negl Trop Dis.* 2009 Sep 1; 3(9):e510.
21. Bhattacharyya T, Mills EA, Miles MA. Prospects for *T. cruzi* lineage-specific serological surveillance of wild mammals. *Acta Trop.* 2015 Nov 1; 151:182–6. <https://doi.org/10.1016/j.actatropica.2015.06.017> PMID: 26116784
22. Sturm NR, Campbell DA. Alternative lifestyles: The population structure of *Trypanosoma cruzi*. *Acta Trop.* 2010 Jul 1; 115(1–2):35–43. <https://doi.org/10.1016/j.actatropica.2009.08.018> PMID: 19695212
23. Cortez M, Atayde V, Yoshida N. Host cell invasion mediated by *Trypanosoma cruzi* surface molecule gp82 is associated with F-actin disassembly and is inhibited by enteroinvasive *Escherichia coli*. *Microbes Infect.* 2006 May 1; 8(6):1502–12. <https://doi.org/10.1016/j.micinf.2006.01.007> PMID: 16697683
24. Brenière SF, Bosseno MF, Magallón-Gastelúm E, Castillo Ruvalcaba EG, Gutierrez MS, Montaña Luna EC, et al. Peridomestic colonization of *Triatoma longipennis* (Hemiptera, Reduviidae) and *Triatoma barberi* (Hemiptera, Reduviidae) in a rural community with active transmission of *Trypanosoma cruzi* in Jalisco state, Mexico. *Acta Trop.* 2007 Mar 1; 101(3):249–57. <https://doi.org/10.1016/j.actatropica.2007.02.007> PMID: 17382891
25. Samudio F, Ortega-Barría E, Saldaña A, Calzada J. Predominance of *Trypanosoma cruzi* I among Panamanian sylvatic isolates. *Acta Trop.* 2007 Feb; 101(2):178–81. <https://doi.org/10.1016/j.actatropica.2006.12.008> PMID: 17288977
26. Jansen AM, Santos De Pinho AP, Lisboa CV, Cupolillo E, Mangia RH, Fernandes O. The Sylvatic Cycle of *Trypanosoma cruzi*: A Still Unsolved Puzzle. *Mem Inst Oswaldo Cruz.* 1999; 94(SUPPL. 1):203–4. <https://doi.org/10.1590/s0074-02761999000700030> PMID: 10677716
27. Yeo M, Acosta N, Llewellyn M, Sánchez H, Adamson S, Miles GAJ, et al. Origins of Chagas disease: *Didelphis* species are natural hosts of *Trypanosoma cruzi* I and armadillos hosts of *Trypanosoma cruzi* II, including hybrids. *Int J Parasitol.* 2005 Feb; 35(2):225–33. <https://doi.org/10.1016/j.ijpara.2004.10.024> PMID: 15710443
28. Ceballos LA, Cardinal M V., Vazquez-Prokopec GM, Lauricella MA, Orozco MM, Cortinas R, et al. Long-term reduction of *Trypanosoma cruzi* infection in sylvatic mammals following deforestation and sustained vector surveillance in northwestern Argentina. *Acta Trop.* 2006 Jul; 98(3):286–96. <https://doi.org/10.1016/j.actatropica.2006.06.003> PMID: 16839513

29. Roellig DM, Brown EL, Barnabé C, Tibayrenc M, Steurer FJ, Yabsley MJ. Molecular typing of *Trypanosoma cruzi* isolates, United States. *Emerg Infect Dis*. 2008 Jul; 14(7):1123–5. <https://doi.org/10.3201/eid1407.080175> PMID: 18598637
30. Bosseno MF, Barnabé C, Gastélum EM, Lozano Kasten F, Ramsey J, Espinoza B, et al. Predominance of *Trypanosoma cruzi* lineage I in Mexico. *J Clin Microbiol*. 2002; 40(2):627–32. <https://doi.org/10.1128/jcm.40.2.627-632.2002> PMID: 11825982
31. Martínez I, Nogueira B, Martínez-Hernández F, Espinoza B. Microsatellite and Mini-Exon analysis of Mexican human DTU I *Trypanosoma cruzi* strains and their susceptibility to nifurtimox and benznidazole. *Vector-Borne Zoonotic Dis*. 2013 Mar 1; 13(3):181–7.
32. Anez N, Crisante G, Silva FM da, Rojas A, Carrasco H, Umezawa ES, et al. Predominance of lineage I among *Trypanosoma cruzi* isolates from Venezuelan patients with different clinical profiles of acute Chagas' disease. *Trop Med Int Heal*. 2004 Dec 1; 9(12):1319–26.
33. Cuervo P, Cupolillo E, Segura I, Saravia N, Fernandes O. Genetic diversity of Colombian sylvatic *Trypanosoma cruzi* isolates revealed by the ribosomal DNA. *Mem Inst Oswaldo Cruz*. 2002; 97(6):877–80.
34. Triana O, Ortiz S, Dujardin JC, Solari A. *Trypanosoma cruzi*: Variability of stocks from Colombia determined by molecular karyotype and minicircle Southern blot analysis. *Exp Parasitol*. 2006 May; 113(1):62–6. <https://doi.org/10.1016/j.exppara.2005.11.016> PMID: 16388803
35. Salazar A, Schijman AG, Triana-Chávez O. High variability of Colombian *Trypanosoma cruzi* lineage I stocks as revealed by low-stringency single primer-PCR minicircle signatures. *Acta Trop*. 2006 Nov 1; 100(1–2):110–8. <https://doi.org/10.1016/j.actatropica.2006.10.003> PMID: 17101108
36. Herrera C, Bagues MD, Fajardo A, Montilla M, Triana O, Vallejo GA, et al. Identifying four *Trypanosoma cruzi* I isolate haplotypes from different geographic regions in Colombia. *Infect Genet Evol*. 2007 Jul 1; 7(4):535–9. <https://doi.org/10.1016/j.meegid.2006.12.003> PMID: 17287152
37. Saldaña A, Santamaría AM, Pineda V, Vásquez V, Gottdenker NL, Calzada JE. A darker chromatic variation of *Rhodnius pallescens* infected by specific genetic groups of *Trypanosoma rangeli* and *Trypanosoma cruzi* from Panama. *Parasit Vectors*. 2018 Dec 16; 11(1):423.
38. Carrasco HJ, Segovia M, Llewellyn MS, Morocoima A, Urdaneta-Morales S, Martínez C, et al. Geographical Distribution of *Trypanosoma cruzi* Genotypes in Venezuela. Büscher P, editor. *PLoS Negl Trop Dis*. 2012 Jun 26; 6(6):e1707. <https://doi.org/10.1371/journal.pntd.0001707> PMID: 22745843
39. Hernández C, Salazar C, Brochero H, Teherán A, Buitrago LS, Vera M, et al. Untangling the transmission dynamics of primary and secondary vectors of *Trypanosoma cruzi* in Colombia: parasite infection, feeding sources and discrete typing units. *Parasit Vectors*. 2016 Dec 1; 9(1):620. <https://doi.org/10.1186/s13071-016-1907-5> PMID: 27903288
40. Hernández C, Cucunubá Z, Flórez C, Olivera M, Valencia C, Zambrano P, et al. Molecular Diagnosis of Chagas Disease in Colombia: Parasitic Loads and Discrete Typing Units in Patients from Acute and Chronic Phases. Debrabant A, editor. *PLoS Negl Trop Dis*. 2016 Sep 20; 10(9):e0004997. <https://doi.org/10.1371/journal.pntd.0004997> PMID: 27648938
41. Velásquez-Ortiz N, Hernández C, Herrera G, Cruz-Saavedra L, Higuera A, Arias-Giraldo LM, et al. *Trypanosoma cruzi* infection, discrete typing units and feeding sources among *Psammolestes arthuri* (Reduviidae: Triatominae) collected in eastern Colombia. *Parasit Vectors*. 2019 Dec 8; 12(1):157. <https://doi.org/10.1186/s13071-019-3422-y> PMID: 30961657
42. Sousa OE. Anotaciones Sobre la enfermedad de Chagas en Panamá. Frecuencia y Distribución de *Trypanosoma cruzi* y *Trypanosoma rangeli*. 1972; 20:167–9.
43. Sousa OE, Johnson CM. Prevalence of *Trypanosoma cruzi* and *Trypanosoma rangeli* in triatomines (Hemiptera: Reduviidae) collected in the Republic of Panama. *Am J Trop Med Hyg*. 1973 Jan; 22(1):18–23. <https://doi.org/10.4269/ajtmh.1973.22.18> PMID: 4567850
44. Organización Panamericana de la Salud (OPS-PAHO) (2006). “Estimación cuantitativa de la enfermedad de Chagas en las Américas”. OMS, Montevideo, Uruguay. OPS/HDM/CD/425-06.
45. Vasquez AM de, Samudio FE, Saldaña A, Paz HM, Calzada JE. Eco-epidemiological aspects of *Trypanosoma cruzi*, *Trypanosoma rangeli* and their vector (*Rhodnius pallescens*) in Panama. *Rev Inst Med Trop Sao Paulo*. 2004 Aug; 46(4):217–22. <https://doi.org/10.1590/s0036-46652004000400008> PMID: 15361974
46. Pineda V, Montalvo E, Alvarez D, Santamaría a. M, Calzada JE, Saldaña A. Feeding sources and trypanosome infection index of *Rhodnius pallescens* in a Chagas disease endemic area of Amador County, Panama. *Rev Inst Med Trop Sao Paulo*. 2008; 50(0816):113–6.
47. Saldaña A, Samudio F, Miranda A, Herrera LM, Saavedra SP, Cáceres L, et al. Predominance of *Trypanosoma rangeli* infection in children from a Chagas disease endemic area in the west-shore of the Panama canal. *Mem Inst Oswaldo Cruz*. 2005 Nov; 100(7):729–31. <https://doi.org/10.1590/s0074-02762005000700008> PMID: 16410959

48. Calzada JE, Pineda V, Garisto JD, Samudio F, Santamaria AM, Saldaña A. Human trypanosomiasis in the eastern region of the Panama Province: new endemic areas for Chagas disease. *Am J Trop Med Hyg.* 2010 Apr; 82(4):580–2. <https://doi.org/10.4269/ajtmh.2010.09-0397> PMID: 20348502
49. Saldaña A, Pineda V, Martínez I, Santamaria G, Santamaria AM, Miranda A, et al. A New Endemic Focus of Chagas Disease in the Northern Region of Veraguas Province, Western Half Panama, Central America. *PLoS One.* 2012; 7(4):e34657. <https://doi.org/10.1371/journal.pone.0034657> PMID: 22558095
50. Calzada JE, Garisto J, Zebedes S, Samudio FE, Blandón R, Avilés O, et al. Prevalence of autoantibodies against autonomic receptors in patients with chronic cardiopathies. *Biomedica.* 2009; 29(1):133–9. PMID: 19753847
51. Gürtler RE, Yadon ZE. Eco-bio-social research on community-based approaches for Chagas disease vector control in Latin America. *Trans R Soc Trop Med Hyg.* 2015 Feb; 109(2):91–8. <https://doi.org/10.1093/trstmh/tru203> PMID: 25604759
52. Ministerio de Salud.(MINS). Boletín Epidemiológico de Enfermedad de Chagas, 2017. Panamá; 2018.
53. Rodríguez IG, Loaiza JR. American trypanosomiasis, or Chagas disease, in Panama: a chronological synopsis of ecological and epidemiological research. *Parasit Vectors.* 2017 Oct 10; 10(1):459. <https://doi.org/10.1186/s13071-017-2380-5> PMID: 29017584
54. Romaña CA, Brunstein D, Collin-Delavaud A, Sousa O, Ortega-Barría E. Public policies of development in Latin America and Chagas' disease. *Lancet (London, England).* 2003 Aug 16; 362(9383):579. [https://doi.org/10.1016/S0140-6736\(03\)14132-3](https://doi.org/10.1016/S0140-6736(03)14132-3) PMID: 12932401
55. Gottdenker NL, Calzada JE, Saldaña A, Carroll CR. Association of anthropogenic land use change and increased abundance of the Chagas disease vector *Rhodnius pallescens* in a rural landscape of Panama. *Am J Trop Med Hyg.* 2011 Jan; 84(1):70–7. <https://doi.org/10.4269/ajtmh.2011.10-0041> PMID: 21212205
56. Gottdenker NL, Chaves LF, Calzada JE, Saldaña A, Carroll CR. Host Life History Strategy, Species Diversity, and Habitat Influence *Trypanosoma cruzi* Vector Infection in Changing Landscapes. *PLoS Negl Trop Dis.* 2012; 6(11):5–7.
57. Sousa OE, Samudio F, de Juncá C, Calzada JE. Molecular characterization of human *Trypanosoma cruzi* isolates from endemic areas in Panama. *Mem Inst Oswaldo Cruz.* 2006 Jun; 101(4):455–7. <https://doi.org/10.1590/s0074-02762006000400018> PMID: 16951819
58. Garisto-Risco JD, Saldaña A, Zebede S, Calzada JE. Cardiac Disease in Seropositive Chagasic Patients in Panama. *Rev Española Cardiol (English Ed.)* 2009 Aug 1; 62(8):947–8.
59. Blandon R. Tránsito esofágico en Pacientes con enfermedad de Chagas en Panamá. *arq Gastroenterol.* 1969; 6:189–96.
60. Brandao A, Samudio F, Fernandes O, Calzada JE, Sousa OE. Genotyping of Panamanian *Trypanosoma cruzi* stocks using the calmodulin 3'UTR polymorphisms. *Parasitol Res.* 2008 Feb 29; 102(3):523–6.
61. Sousa OE. Anotaciones sobre la enfermedad de Chagas. Frecuencia y distribución de *Trypanosoma cruzi* y *Trypanosoma rangeli*. *Rev Biol Trop.* 1971; 20(2).
62. Avila HA, Sigman DS, Cohen LM, Millikan RC, Simpson L. Polymerase chain reaction amplification of *Trypanosoma cruzi* kinetoplast minicircle DNA isolated from whole blood lysates: diagnosis of chronic Chagas' disease. *Mol Biochem Parasitol.* 1991 Oct 1; 48(2):211–21. [https://doi.org/10.1016/0166-6851\(91\)90116-n](https://doi.org/10.1016/0166-6851(91)90116-n) PMID: 1662334
63. Saldaña A, Sousa OE, Orn A. Immunoparasitological Studies of *Trypanosoma Cruzi* Low Virulence Clones from Panama: Humoral Immune Responses and Antigenic Cross-Reactions with *Trypanosoma Rangeli* in Experimentally Infected Mice. *Scand J Immunol.* 1995 Dec 1; 42(6):644–50. <https://doi.org/10.1111/j.1365-3083.1995.tb03707.x> PMID: 8552988
64. Cura CI, Duffy T, Lucero RH, Bisio M, Péneau J, Jimenez-Coello M, et al. Multiplex Real-Time PCR Assay Using TaqMan Probes for the Identification of *Trypanosoma cruzi* DTUs in Biological and Clinical Samples. *PLoS Negl Trop Dis.* 2015 May 19; 9(5). <https://doi.org/10.1371/journal.pntd.0003765> PMID: 25993316
65. Burgos JM, Diez M, Vigliano C, Bisio M, Riso M, Duffy T, et al. Molecular Identification of *Trypanosoma cruzi* Discrete Typing Units in End-Stage Chronic Chagas Heart Disease and Reactivation after Heart Transplantation. *Clin Infect Dis.* 2010 Sep 1; 51(5):485–95. <https://doi.org/10.1086/655680> PMID: 20645859
66. Zulantay I, Apt W, Gil LC, Rocha C, Mundaca K, Solari A, et al. The PCR-based detection of *Trypanosoma cruzi* in the faeces of *Triatoma infestans* fed on patients with chronic American trypanosomiasis gives higher sensitivity and a quicker result than routine xenodiagnosis. *Ann Trop Med Parasitol.* 2007 Dec; 101(8):673–9. <https://doi.org/10.1179/136485907X241415> PMID: 18028728

67. Guhl F. Chagas disease in Andean countries. *Mem Inst Oswaldo Cruz*. 2007 Aug 31; 102(suppl 1):29–38. <https://doi.org/10.1590/s0074-02762007005000099> PMID: 17891273
68. Olivera MJ, Fory JA, Porras JF, Buitrago G. Prevalence of Chagas disease in Colombia: A systematic review and meta-analysis. Gourbiere S, editor. *PLoS One*. 2019 Jan 7; 14(1):e0210156. <https://doi.org/10.1371/journal.pone.0210156> PMID: 30615644
69. Burgos JM, Altchek J, Bisio M, Duffy T, Valadares HMS, Seidenstein ME, et al. Direct molecular profiling of minicircle signatures and lineages of *Trypanosoma cruzi* bloodstream populations causing congenital Chagas disease. *Int J Parasitol*. 2007 Oct 1; 37(12):1319–27. <https://doi.org/10.1016/j.ijpara.2007.04.015> PMID: 17570369
70. Coura JR, Junqueira ACV, Boia MN, Fernandes O. Chagas Disease: From Bush to Huts and Houses. Is it the Case of the Brazilian Amazon? *Mem Inst Oswaldo Cruz*. 1999; 94(SUPPL. 1):379–84. <https://doi.org/10.1590/s0074-02761999000700074> PMID: 10677760
71. Ruíz-Sánchez R, De León MP, Matta V, Reyes PA, López R, Jay D, et al. *Trypanosoma cruzi* isolates from Mexican and Guatemalan acute and chronic chagasic cardiopathy patients belong to *Trypanosoma cruzi* I. *Mem Inst Oswaldo Cruz*. 2005; 100(3):281–3. <https://doi.org/10.1590/s0074-02762005000300012> PMID: 16113869
72. Panesso-Gómez S, Pavia P, Rodríguez-Mantilla IE, Lasso P, Orozco LA, Cuellar A, et al. *Trypanosoma cruzi* detection in colombian patients with a diagnosis of esophageal Achalasia. *Am J Trop Med Hyg*. 2018; 98(3):717–23. <https://doi.org/10.4269/ajtmh.17-0417> PMID: 29405099
73. Mantilla JC, Zafra GA, Macedo AM, González CI. Mixed infection of *Trypanosoma cruzi* I and II in a Colombian cardiomyopathic patient. *Hum Pathol*. 2010 Apr 1; 41(4):610–3. <https://doi.org/10.1016/j.humpath.2009.11.005> PMID: 20153511
74. Dario MA, Rodrigues MS, Barros JHDS, Xavier SCDC, D'Andrea PS, Roque ALR, et al. Ecological scenario and *Trypanosoma cruzi* DTU characterization of a fatal acute Chagas disease case transmitted orally (Espírito Santo state, Brazil). *Parasit Vectors*. 2016 Dec 31; 9(1):477.
75. Vago AR, Andrade LO, Leite AA, d'Ávila Reis D, Macedo AM, Adad SJ, et al. Genetic characterization of *Trypanosoma cruzi* directly from tissues of patients with chronic chagas disease: Differential distribution of genetic types into diverse organs. *Am J Pathol*. 2000; 156(5):1805–9. [https://doi.org/10.1016/s0002-9440\(10\)65052-3](https://doi.org/10.1016/s0002-9440(10)65052-3) PMID: 10793092
76. Monje-Rumi MM, Brandán CP, Ragone PG, Tomasini N, Lauthier JJ, Alberti D'Amato AM, et al. *Trypanosoma cruzi* diversity in the Gran Chaco: Mixed infections and differential host distribution of TcV and TcVI. *Infect Genet Evol*. 2015 Jan 1; 29:53–9. <https://doi.org/10.1016/j.meegid.2014.11.001> PMID: 25445658
77. Duz ALC, Vieira PMDA, Roatt BM, Aguiar-Soares RDO, Cardoso JM de O, de Oliveira FCB, et al. The TcI and TcII *Trypanosoma cruzi* experimental infections induce distinct immune responses and cardiac fibrosis in dogs. *Mem Inst Oswaldo Cruz*. 2014 Dec 1; 109(8):1005–13. <https://doi.org/10.1590/0074-02760140208> PMID: 25591108
78. Sales-Campos H, Kappel HB, Andrade CP, Lima TP, Mattos ME, de Castilho A, et al. A DTU-dependent blood parasitism and a DTU-independent tissue parasitism during mixed infection of *Trypanosoma cruzi* in immunosuppressed mice. *Parasitol Res*. 2014 Jan 1; 113(1):375–85. <https://doi.org/10.1007/s00436-013-3665-z> PMID: 24178748
79. Sales-Campos H, Kappel HB, Andrade CP, Lima TP, Castilho A De, Giraldo LER, et al. *Trypanosoma cruzi* DTU TcII presents higher blood parasitism than DTU TcI in an experimental model of mixed infection. *Acta Parasitol*. 2015 Jan 1; 60(3):435–41. <https://doi.org/10.1515/ap-2015-0060> PMID: 26204180
80. Santi-Rocca J, Fernandez-Cortes F, Chillón-Marinás C, González-Rubio ML, Martin D, Gironès N, et al. A multi-parametric analysis of *Trypanosoma cruzi* infection: Common pathophysiologic patterns beyond extreme heterogeneity of host responses. *Sci Rep*. 2017 Dec 1; 7(1). <https://doi.org/10.1038/s41598-017-08086-8> PMID: 28827716
81. Llewellyn MS, Miles MA, Carrasco HJ, Lewis MD, Yeo M, Vargas J, et al. Genome-scale multilocus microsatellite typing of *Trypanosoma cruzi* discrete typing unit I reveals phylogeographic structure and specific genotypes linked to human infection. *PLoS Pathog*. 2009 May; 5(5). <https://doi.org/10.1371/journal.ppat.1000410> PMID: 19412340